Adaptive Biotechnologies
ADPT
207 hedge funds and large institutions have $859M invested in Adaptive Biotechnologies in 2024 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 67 increasing their positions, 45 reducing their positions, and 23 closing their positions.
100% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 23
49% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 45
17% more capital invested
Capital invested by funds: $732M → $859M (+$126M)
11% more funds holding
Funds holding: 187 → 207 (+20)
9% more call options, than puts
Call options by funds: $178K | Put options by funds: $163K
0.05% more ownership
Funds ownership: 97.04% → 97.09% (+0.05%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
+$13.2M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$10.3M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.61M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.78M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$17.1M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$12M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$7.03M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$4.97M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$4.97M |
ADPT Hedge Fund Activity: Q4 2024 in Review
207 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q4 2024, worth a combined $859M — up 17% from $732M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ADPT positions and 23 closed out — a net gain of 23 holders — while 67 added to existing stakes and 45 trimmed.
The largest buyer was VOYA Investment Management, adding an estimated $13.2M. The largest seller was Millennium Management, cutting an estimated $17.1M.
- 207 institutional investors held Adaptive Biotechnologies (ADPT) as of Q4 2024, up from 187 in Q3 2024.
- Funds reported $859M of Adaptive Biotechnologies stock for Q4 2024, up 17% quarter-over-quarter.
- 46 funds opened new Adaptive Biotechnologies positions in Q4 2024 and 23 closed out, a net change of +23 holders.
- The largest Adaptive Biotechnologies buyer in Q4 2024 was VOYA Investment Management, an estimated $13.2M added.
- The largest Adaptive Biotechnologies seller in Q4 2024 was Millennium Management, an estimated $17.1M sold.
Based on aggregated 13F filings for Q4 2024.